Refractory IPA clinical trials at UCLA
1 research study open to eligible people
Showing trials for
PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
open to eligible people ages 18 years and up
To assess the safety and efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA
Los Angeles 5368361, California 5332921 and other locations
Our lead scientists for Refractory IPA research studies include Joanna M. Schaenman, MD, PhD.
Last updated: